Abraxane monotherapy is indicated for the treatment of metastatic breast cancer The recommended dose of Abraxane in combination with gemcitabine is Attachment 1: Product information for AusPAR Abraxane paclitaxel (nab) Abraxis PM Date of Finalisation 17 June This Product. Learn more about ABRAXANE®, including dosing, efficacy, and safety information. This site is intended for US healthcare professionals only.
|Published (Last):||21 July 2014|
|PDF File Size:||3.38 Mb|
|ePub File Size:||2.16 Mb|
|Price:||Free* [*Free Regsitration Required]|
Importantly, nab-paclitaxel has demonstrated limited taxane cross-resistance. Several limitations in the present study need to be acknowledged. Methods Women with mbc treated with single-agent nab-paclitaxel between June and December were included in this analysis.
ABRAXANE – Prescribing Information
Clinical benefit was achieved in 24 patients Our clinical experience demonstrates that most women treated with nab-paclitaxel experienced some clinical benefit. In an exploratory analysis, the relative risk of death for various patient subgroups was estimated using Cox proportional hazards regression. Nab-paclitaxel is a solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer mbc.
Paclitaxel and docetaxel are both hydrophobic, and to enable intravenous administration, they are formulated using the synthetic solvents polyoxyethylated castor oil Cremophor EL: Eligible patients for this study included all women with mbc who were treated with single-agent nab-paclitaxel at the Ottawa Hospital Cancer Centre. One patient experienced febrile neutropenia. The odds ratio for achieving clinical benefit with the qw schedule was 2.
Notably, clinical benefit was also seen in heavily pretreated women median of 3 cycles of chemotherapy before nab-paclitaxel and those previously exposed to taxanes in the adjuvant and metastatic settings.
Median duration of therapy was 5. Support Center Support Center.
Find articles by M. Retrospective data obtained included demographics, disease characteristics, prior chemotherapy, nab-paclitaxel treatment, toxicity, and survival.
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Survival curves for patients receiving weekly Q-weekly and everyweeks Q3-weekly nab-paclitaxel.
Survival curves were generated using the Kaplan—Meier method and were compared using the log-rank test. Regardless of dosing schedule, women experiencing clinical benefit lived significantly longer than those not experiencing a benefit That trial will evaluate the relationships of sparc overexpression and of changes in blood levels of caveolin 1 with progression-free survival and secondary endpoints of response during treatment.
Demographic and treatment characteristics of patients with metastatic breast cancer receiving nab-paclitaxel. Every 3 weeks q3w.
Phase ii trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: Pharmacological ;i of formulation vehicles: Median survivals were 7.
Of 43 women mean age: Nab-paclitaxel is a colloidal suspension of paclitaxel and human serum albumin that can be administered without premedication Abraxane PI, Abraxane PM: Peripheral neuropathy induced by paclitaxel: Most patients also had several sites of metastases Clinical benefit was evaluable in 42 patients. It is this drug entrapment phenomenon that partly explains why giving higher doses of solvent-based paclitaxel does not result in improved clinical efficacy Treatment with nab-paclitaxel was well tolerated.
Abstract Background Nab-paclitaxel is avraxane solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer mbc.
ABRAXANE | Full Prescribing Information
In our experience, most women with mbc treated with single-agent nab-paclitaxel abraxxne having received up to 6 prior lines of chemotherapy experienced some degree of clinical benefit with an acceptable level of toxicity. Peripheral sensory neuropathy was the most commonly reported toxicity, being reported in approximately Clinical benefit was defined as partial or complete response or stable disease by clinical or radiologic evaluation, or both at 6 months or more.
Find articles by G. In the Cox proportional hazards analysis, achievement of clinical benefit hr: Find articles by Abrqxane. A partial response to nab-paclitaxel therapy was seen in 4 patients 9.
In Augustnab-paclitaxel received approval for funding in Ontario for women with mbc. Nab-paclitaxel, taxane, mbcAbraxane. Paclitaxel is entrapped by the formation of plasma Cremophor EL micelles, which can cause reduced drug clearance, nonlinear pharmacokinetics, and free drug fraction The small study population and retrospective nature of the analysis represent significant limitations in interpreting its results.
Find articles by N. Find articles by S.